---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000006"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:52:08.227692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B

## Summary
- Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.
- Full year 2023 sales ~$1.567B, up 53.2% as-reported over prior year.
- Legacy Globus Q4 revenue $302.9M (+10.4% YoY); full year $1.152B (+12.7%).
- FY2024 revenue guidance $2.450-2.475B; non-GAAP EPS guidance $2.68-$2.70.
- Completed NuVasive merger Sept 1, 2023; integration on track with strong sales retention.

## SEC filing metadata
- accession: 0001562762-24-000006
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/0001562762-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/gmed-20240110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000006
- JSON: https://secwatch.observer/filing/0001562762-24-000006.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000006.txt

## Key facts
- Earnings Releases
  GLOBUS MEDICAL INC updated its the three-month period and fiscal year ended December 31, 2023 guidance (initiated).
  - Period: the three-month period and fiscal year ended December 31, 2023
  - Guidance: initiated
  - Result: preliminary results
  source text: On January 10, 2024, we issued a press release reporting our preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2023. The press release also included preliminary guidance for certain financial measures for the 2024 fiscal year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/0001562762-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.